HK1082378A1 - 癌病治療增敏劑 - Google Patents

癌病治療增敏劑

Info

Publication number
HK1082378A1
HK1082378A1 HK06104049.7A HK06104049A HK1082378A1 HK 1082378 A1 HK1082378 A1 HK 1082378A1 HK 06104049 A HK06104049 A HK 06104049A HK 1082378 A1 HK1082378 A1 HK 1082378A1
Authority
HK
Hong Kong
Prior art keywords
cancer therapy
therapy sensitizer
sensitizer
cancer
therapy
Prior art date
Application number
HK06104049.7A
Other languages
English (en)
Inventor
Bo Chen Lan
T Tai Isabelle
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of HK1082378A1 publication Critical patent/HK1082378A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK06104049.7A 2003-01-14 2006-04-03 癌病治療增敏劑 HK1082378A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44000903P 2003-01-14 2003-01-14
PCT/US2004/000901 WO2004064785A2 (en) 2003-01-14 2004-01-14 Cancer therapy sensitizer

Publications (1)

Publication Number Publication Date
HK1082378A1 true HK1082378A1 (zh) 2006-06-09

Family

ID=32771768

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06104049.7A HK1082378A1 (zh) 2003-01-14 2006-04-03 癌病治療增敏劑

Country Status (7)

Country Link
US (2) US7638272B2 (zh)
EP (2) EP2561887B8 (zh)
JP (3) JP5568208B2 (zh)
CA (2) CA2802143C (zh)
ES (2) ES2565327T3 (zh)
HK (1) HK1082378A1 (zh)
WO (1) WO2004064785A2 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US20080268068A1 (en) 2004-11-30 2008-10-30 Tai Isabella T Sparc Promoter Mutations Associated with Drug Resistance, and Methods, Oligonucleotides, Cells and Arrays Associated Therewith
JP2008535475A (ja) * 2005-02-18 2008-09-04 アブラクシス バイオサイエンス、インコーポレイテッド Ｑ３ｓｐａｒｃ欠失変異体及びその使用
ES2406929T3 (es) 2006-06-26 2013-06-10 The University Of British Columbia Proteína secretada ácida y rica en cisteína (SPARC) como sensibilizantes quimioterapéuticos
US20100015128A1 (en) * 2006-10-03 2010-01-21 University Of Southern California GRP78 as a Predictor of Responsiveness to Therapeutic Agents
ES2389828T3 (es) * 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
NZ606480A (en) * 2008-12-05 2014-08-29 Abraxis Bioscience Llc Albumin binding peptide-mediated disease targeting
BRPI1014392A2 (pt) * 2009-05-28 2016-04-05 Abraxis Biosciense Llc uso de anticorpos anti-sparc para prever resposta a quimioterapia
GB201018664D0 (en) * 2010-11-05 2010-12-22 Msd Biolog Uk Ltd Expression process
JP2018533578A (ja) * 2015-10-30 2018-11-15 モナシュ ユニバーシティー グルコース代謝改善のための方法及び組成物
KR101804246B1 (ko) 2015-11-18 2017-12-04 주식회사 메타신 Fstl1 단백질을 유효성분으로 함유하는 골대사성 질환 예방 및 치료용 약학적 조성물
KR101804241B1 (ko) 2015-11-20 2017-12-04 주식회사 메타신 Fstl1 단백질을 유효성분으로 함유하는 암전이 예방 및 치료용 약학적 조성물
KR101804248B1 (ko) 2015-11-25 2017-12-04 주식회사 메타신 Fstl1 단백질을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
US20190381127A1 (en) * 2016-02-02 2019-12-19 Splash Pharmaceuticals, Inc. Combination therapy with a6, chemotherapeutic agents, radiation therapy, or a combination thereof for the treatment of cancer
SE2000055A1 (sv) * 2020-03-15 2021-09-16 Martin Ivanov Denev Användande av fotohydrauliskt mekanisk chock, för selektiv sprängning av relativ svagare cellmembranen av cancerceller, vilka har svagare cellmembran än friska celler

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
JP3015383B2 (ja) 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
WO1989005345A1 (en) 1987-12-11 1989-06-15 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
EP0747485B1 (en) 1989-11-06 1998-12-02 Cell Genesys, Inc. Production of proteins using homologous recombination
JP3501286B2 (ja) 1989-12-22 2004-03-02 アプライド リサーチ システムズ，エーアールエス ホールディング ナームロゼ ベノートスハップ 一定の細胞系又は微生物の内因性遺伝子の発現特徴の変性のための方法
DK0568537T3 (da) 1990-10-31 1998-09-23 Whitehead Biomedical Inst Genetisk modificering af endotelceller
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
WO1994018218A1 (en) * 1993-02-01 1994-08-18 Seq, Ltd. Methods and apparatus for dna sequencing
AU6816194A (en) 1993-04-20 1994-11-08 Robinson, William S. Methods and materials for treatment of individuals infected with intracellular infectious agents
JPH09235223A (ja) * 1995-12-26 1997-09-09 Nisshin Flour Milling Co Ltd 多剤耐性克服剤
AU5431098A (en) 1996-11-07 1998-05-29 Wistar Institute Of Anatomy And Biology, The Sparc-deficient transgenic mice
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
EP0950097A2 (en) 1996-12-27 1999-10-20 Instituto de Investigaciones Bioquimicas Fundacion Campomar Compositions and methods for tumour therapy
WO1998033527A2 (en) 1997-01-31 1998-08-06 Cohen Edward P Cancer immunotherapy with semi-allogeneic cells
DE19740571C1 (de) 1997-09-15 1999-03-18 Gsf Forschungszentrum Umwelt Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität
US6475784B1 (en) * 1997-11-14 2002-11-05 Valentis, Inc. Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides
JP4549529B2 (ja) 1998-01-30 2010-09-22 サイオス，インコーポレーテッド ペプチドまたはタンパク質の制御放出送達
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6316193B1 (en) * 1998-10-06 2001-11-13 Origene Technologies, Inc. Rapid-screen cDNA library panels
US6387664B1 (en) 1999-02-26 2002-05-14 Secretary Of Agency Of Industrial Science And Technology Sparc fusion protein and method for producing the same
CA2374141A1 (en) 1999-05-28 2000-12-07 University Of Virginia Patent Foundation Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues
AU7607900A (en) 1999-09-22 2001-04-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
AU783714B2 (en) 1999-10-04 2005-12-01 Vion Pharmaceuticals, Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
AU2001259131A1 (en) 2000-04-25 2001-11-07 Dna Sciences, Inc. Detection of nucleotide sequence variations via the proofreading activity of polymerases
WO2002002771A2 (en) 2000-07-05 2002-01-10 Eli Lilly And Company Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
WO2004005883A2 (en) 2002-07-02 2004-01-15 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
DE60228419D1 (de) * 2001-02-15 2008-10-02 Sinai School Medicine Hemmung der atf2-aktivität zur behandlung von krebs
WO2002089772A1 (en) * 2001-05-09 2002-11-14 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
WO2003072714A2 (en) * 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
US6814248B2 (en) * 2002-08-08 2004-11-09 Dtl Technology Limited Partnership Plastics container with recessed handgrip features and associated method and apparatus for manufacture thereof
AU2003262717A1 (en) 2002-08-15 2004-03-03 Genzyme Corporation Brain endothelial cell expression patterns
US7485414B2 (en) * 2002-08-30 2009-02-03 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis
EP1514929A1 (en) * 2003-09-12 2005-03-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Antisense oligonucleotides for prevention of metastasis formation of cancer cells

Also Published As

Publication number Publication date
WO2004064785A3 (en) 2005-10-20
EP1594433B1 (en) 2016-01-13
ES2565496T3 (es) 2016-04-05
WO2004064785A2 (en) 2004-08-05
US20100151006A1 (en) 2010-06-17
EP2561887B8 (en) 2016-12-21
ES2565327T3 (es) 2016-04-04
US20060088511A1 (en) 2006-04-27
JP2015057394A (ja) 2015-03-26
CA2802143A1 (en) 2004-08-05
EP2561887A2 (en) 2013-02-27
EP1594433A4 (en) 2008-10-01
JP5568208B2 (ja) 2014-08-06
EP1594433B8 (en) 2016-12-21
CA2513251A1 (en) 2004-08-05
JP2012197294A (ja) 2012-10-18
US7638272B2 (en) 2009-12-29
JP2006517926A (ja) 2006-08-03
CA2802143C (en) 2018-06-19
EP2561887A3 (en) 2013-03-27
EP2561887B1 (en) 2016-01-13
US8071294B2 (en) 2011-12-06
CA2513251C (en) 2013-03-19
EP1594433A2 (en) 2005-11-16
WO2004064785A9 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
HK1082378A1 (zh) 癌病治療增敏劑
EP1482970A4 (en) ANTICANCER THERAPY
EP1535610A4 (en) THERAPEUTIC CANCER
HK1102757A1 (en) Therapy of platinum-resistant cancer
EP1672978A4 (en) COBALAMIN CONJUGATES FOR TUMOR THERAPY
EP1594433A3 (en) Cancer therapy sensitizer
EP1677805A4 (en) TREATMENT OF PANCREATIC CANCER
GB0428187D0 (en) Cancer treatment
GB0327384D0 (en) Gene therapy
GB0326578D0 (en) Cancer diagnosis and therapy
GB0226595D0 (en) Cancer therapy determination
EP1595546A4 (en) REMEDIES AGAINST CANCER
GB0404675D0 (en) Cancer treatment
GB0223325D0 (en) Treating cancer
GB0303289D0 (en) Combination therapy
PL1618130T3 (pl) Szczepionka terapeutyczna przeciw nowotworom
AU2003238722A8 (en) Cancer therapy by modulating cdc42-activity
GB2383538B (en) Cancer treatment
GB0414885D0 (en) Cancer therapy
GB0327499D0 (en) Cancer treatment
EP1646282A4 (en) ANTICANCER GENETIC VACCINES
GB0218725D0 (en) Cancer related methods
GB0213474D0 (en) Tumour therapy
GB0329081D0 (en) Radiotherapy apparatus
GB0316176D0 (en) Combination therapy

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME AND ADDRESS OF APPLICANT/PROPRIETOR FRO

Effective date: 20180201

PE Patent expired

Effective date: 20240113